{
  "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "docSlug": "2296286e07283457e97b21dc9ce59469",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 46,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Includes a comparison table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/14",
  "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "deckJsonHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0.json",
  "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.48,
        "x": 0.02,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Hematologic Cancers Market Size",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af9bdbfc-922e-4a71-8ffb-1c8b98b0f82f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.48,
        "x": 0.02,
        "y": 0.38
      },
      "kind": "list",
      "text": "Multiple Myeloma (\"MM\") is 3rd most common blood cancer, impacting 176,404 patients annually, with life expectancy of 5 years. AL Amyloidosis is developed by 14,982 people annually—with no available treatments as standard of care.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e138f06-9ab4-4723-872d-aff1d6f7b7a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.46,
        "x": 0.52,
        "y": 0.3
      },
      "kind": "list",
      "text": "1. Leveraging market CAR-T experience... 2. Demand for MM CAR-Ts exceeds supply... 3. Still common with approved CAR-Ts: High grade Cytokine Release Syndrome... 4. Bispecifics/Allogeneic CAR-Ts still work in progress.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a5648b7-0569-4903-9fe6-573805cadcbd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.48,
        "x": 0.02,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Hematologic cancers market opportunity is $60bn today growing to $120bn in 2028.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "433f4720-9abf-4ded-a67d-16d318d68da0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Sources: Multiple Myeloma life expectancy source - Arcellx July 2022 investor presentation... (etc)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc13a02c-1eb1-431d-99f5-8a177550cab9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.46,
        "x": 0.52,
        "y": 0.75
      },
      "kind": "table",
      "text": "NXC-201 vs Allogeneic CAR-T vs BCMA bispecific engagers performance metrics",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffc730af-db12-4009-86ac-aa82762e7c40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "NXC-201 Entering Large Markets At a Pivotal Moment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c9e65da-2706-41e0-85dd-79461097fe03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.46,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "title",
      "text": "Why Now",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af31a2cf-5581-471c-b750-7f40019432c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.48,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "title",
      "text": "Market Size",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee065c38-baa7-4e8a-9d46-f6f890b230fe",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "70d0aa9b-23a7-4091-80be-8de914afb0c0",
      "evidence": "list/bullet: Multiple Myeloma (\"MM\") is 3rd most common blood cancer, impacting 176,404 patients annually",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "why_now",
      "slug": null,
      "matchId": "900afe68-f1b6-4a0d-874e-86685e44a827",
      "evidence": "Slide explicitly titled 'Why Now' with numbered arguments for market entry timing.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "ec348a34-4a83-4f17-b0f0-268fe2d31e3a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation presents Immix Biopharma's solutions and clinical results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "d3ed2b4b-7476-486a-bc9e-587ba67669a2",
      "evidence": "The presentation presents clinical results and data to support the solutions.",
      "position": 1,
      "objective": "What are the potential benefits of Immix Biopharma's solutions?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}